» Articles » PMID: 12033383

A Spectroscopic Investigation of Hydrogen Bond Patterns in Crystalline and Amorphous Phases in Dihydropyridine Calcium Channel Blockers

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2002 May 30
PMID 12033383
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To gain insight into the molecular structure of amorphous compounds by investigating hydrogen bonding patterns and strength in a series of structurally related compounds. Seven 1,4-dihydropyridine calcium channel blockers were evaluated.

Methods: FT-Raman and FT-infrared spectra of the compounds in the crystalline and amorphous states were obtained.

Results: For crystalline compounds, the position of the NH vibration varied considerably. indicating that the strength of hydrogen bonding differs between the different compounds in agreement with published single crystal X-ray data. For the amorphous phases, the NH vibration occurred at approximately the same position for all compounds, suggesting a uniform average hydrogen bonding strength. Somewhat surprisingly, for some compounds, the average hydrogen bond strength in the amorphous state was found to be greater than in the crystalline compound, although for others, it was weaker as anticipated. Hydrogen bonding patterns (acceptor group) varied between the crystalline compounds, but were remarkably consistent in the amorphous compounds; thus the acceptor group in the amorphous phase is not necessarily the same as in the crystalline counterpart.

Conclusions: Hydrogen bond patterns and strength within a group of chemically related amorphous compounds were found to be very similar, but were different from those in the equivalent group of crystalline substances.

Citing Articles

The Amorphous Solid Dispersion of Chrysin in Plasdone S630 Demonstrates Improved Oral Bioavailability and Antihyperlipidemic Performance in Rats.

Wang C, Liu X, Zhao R, Yang M, Liu W, Dai Q Pharmaceutics. 2023; 15(10).

PMID: 37896138 PMC: 10610386. DOI: 10.3390/pharmaceutics15102378.


Tailored Supersaturable Immediate Release Behaviors of Hypotensive Supersaturating Drug-Delivery Systems Combined with Hot-Melt Extrusion Technique and Self-Micellizing Polymer.

Yu H, Ma Y, Zhang Y, Zhang H, Zuo L, Hao C Polymers (Basel). 2022; 14(22).

PMID: 36432925 PMC: 9693352. DOI: 10.3390/polym14224800.


Comparison of the physical and thermodynamic stability of amorphous azelnidipine and its coamorphous phase with piperazine.

Du S, Li W, Wu Y, Fu Y, Yang C, Wang J RSC Adv. 2022; 8(57):32756-32764.

PMID: 35547669 PMC: 9086389. DOI: 10.1039/c8ra05535a.


Exploring molecular reorientations in amorphous and recrystallized felodipine at the microscopic level.

Pajzderska A, Jenczyk J, Embs J, Wasicki J RSC Adv. 2022; 10(61):37346-37357.

PMID: 35521258 PMC: 9057141. DOI: 10.1039/d0ra07266d.


The Physical Stability of Felodipine and Its Recrystallization from an Amorphous Solid Dispersion Studied by NMR Relaxometry.

Pajzderska A, Mielcarek J, Wasicki J AAPS PharmSciTech. 2022; 23(4):93.

PMID: 35314906 DOI: 10.1208/s12249-022-02234-8.


References
1.
Wang S, Herbette L, Rhodes D . Structure of the calcium channel antagonist, nimodipine. Acta Crystallogr C. 1989; 45 ( Pt 11):1748-51. DOI: 10.1107/s010827018900329x. View

2.
Fossheim R, Joslyn A, SOLO A, Luchowski E, Rutledge A, Triggle D . Crystal structures and pharmacologic activities of 1,4-dihydropyridine calcium channel antagonists of the isobutyl methyl 2,6-dimethyl-4-(substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nisoldipine) series. J Med Chem. 1988; 31(2):300-5. DOI: 10.1021/jm00397a005. View

3.
Burger A, Rollinger J, Bruggeller P . Binary system of (R)- and (S)-nitrendipine--polymorphism and structure. J Pharm Sci. 1997; 86(6):674-9. DOI: 10.1021/js9604772. View

4.
TAYLOR L, Zografi G . Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci. 1999; 87(12):1615-21. DOI: 10.1021/js9800174. View

5.
Triggle A, SHEFTER E, Triggle D . Crystal structures of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-[2-nitro-, 3-cyano-, 4-(dimethylamino)-, and 2,3,4,5,6-pentafluorophenyl]-1,4-dihydropyridine. J Med Chem. 1980; 23(12):1442-5. DOI: 10.1021/jm00186a029. View